Does the media refer more to TNXP or CYRX?

In the previous week, Tonix Pharmaceuticals and Tonix Pharmaceuticals both had 2 articles in the media. CryoPort's average media sentiment score of 0.84 beat Tonix Pharmaceuticals' score of 0.17 indicating that CryoPort is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral CryoPort 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TNXP or CLYM?

In the previous week, Tonix Pharmaceuticals and Tonix Pharmaceuticals both had 2 articles in the media. Climb Bio's average media sentiment score of 0.37 beat Tonix Pharmaceuticals' score of 0.17 indicating that Climb Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Climb Bio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TNXP or OCS?

In the previous week, Tonix Pharmaceuticals had 1 more articles in the media than Oculis. MarketBeat recorded 2 mentions for Tonix Pharmaceuticals and 1 mentions for Oculis. Tonix Pharmaceuticals' average media sentiment score of 0.17 beat Oculis' score of 0.00 indicating that Tonix Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Oculis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TNXP or ACRS?

In the previous week, Aclaris Therapeutics had 1 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 3 mentions for Aclaris Therapeutics and 2 mentions for Tonix Pharmaceuticals. Aclaris Therapeutics' average media sentiment score of 0.76 beat Tonix Pharmaceuticals' score of 0.17 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Aclaris Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tonix Pharmaceuticals (TNXP) Competitors

$10.98 -1.45 (-11.67%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$11.07 +0.09 (+0.82%)

As of 04:05 AM Eastern

Compare

TNXP vs. CYRX, CLYM, OCS, ZVRA, and ACRS

Should you buy Tonix Pharmaceuticals stock or one of its competitors? MarketBeat compares Tonix Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tonix Pharmaceuticals include CryoPort (CYRX), Climb Bio (CLYM), Oculis (OCS), Zevra Therapeutics (ZVRA), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry.

How does Tonix Pharmaceuticals compare to CryoPort?

Tonix Pharmaceuticals (NASDAQ:TNXP) and CryoPort (NASDAQ:CYRX) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

CryoPort has a net margin of 41.57% compared to Tonix Pharmaceuticals' net margin of -839.52%. CryoPort's return on equity of -7.92% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%
CryoPort	41.57%	-7.92%	-4.79%

CryoPort has higher revenue and earnings than Tonix Pharmaceuticals. Tonix Pharmaceuticals is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$13.11M	13.35	-$124.02M	-$14.36	N/A
CryoPort	$182.94M	4.33	$78.30M	$1.35	11.64

Tonix Pharmaceuticals has a beta of 1.64, indicating that its share price is 64% more volatile than the broader market. Comparatively, CryoPort has a beta of 1.88, indicating that its share price is 88% more volatile than the broader market.

82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.9% of CryoPort shares are owned by institutional investors. 2.0% of Tonix Pharmaceuticals shares are owned by insiders. Comparatively, 9.5% of CryoPort shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Tonix Pharmaceuticals presently has a consensus target price of $24.00, indicating a potential upside of 118.58%. CryoPort has a consensus target price of $15.11, indicating a potential downside of 3.81%. Given Tonix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Tonix Pharmaceuticals is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Tonix Pharmaceuticals and Tonix Pharmaceuticals both had 2 articles in the media. CryoPort's average media sentiment score of 0.84 beat Tonix Pharmaceuticals' score of 0.17 indicating that CryoPort is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tonix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
CryoPort	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CryoPort beats Tonix Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to Climb Bio?

Tonix Pharmaceuticals (NASDAQ:TNXP) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 2.0% of Tonix Pharmaceuticals shares are held by company insiders. Comparatively, 2.6% of Climb Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Tonix Pharmaceuticals has a beta of 1.64, suggesting that its share price is 64% more volatile than the broader market. Comparatively, Climb Bio has a beta of 0.07, suggesting that its share price is 93% less volatile than the broader market.

Tonix Pharmaceuticals currently has a consensus price target of $24.00, suggesting a potential upside of 118.58%. Climb Bio has a consensus price target of $21.73, suggesting a potential upside of 77.80%. Given Tonix Pharmaceuticals' higher probable upside, research analysts plainly believe Tonix Pharmaceuticals is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

In the previous week, Tonix Pharmaceuticals and Tonix Pharmaceuticals both had 2 articles in the media. Climb Bio's average media sentiment score of 0.37 beat Tonix Pharmaceuticals' score of 0.17 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tonix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Climb Bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Climb Bio has lower revenue, but higher earnings than Tonix Pharmaceuticals. Climb Bio is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$13.11M	13.35	-$124.02M	-$14.36	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

Climb Bio has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -839.52%. Climb Bio's return on equity of -31.45% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%
Climb Bio	N/A	-31.45%	-30.39%

Summary

Climb Bio beats Tonix Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to Oculis?

Tonix Pharmaceuticals (NASDAQ:TNXP) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Tonix Pharmaceuticals currently has a consensus price target of $24.00, suggesting a potential upside of 118.58%. Oculis has a consensus price target of $38.33, suggesting a potential upside of 226.80%. Given Oculis' higher possible upside, analysts plainly believe Oculis is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Oculis has lower revenue, but higher earnings than Tonix Pharmaceuticals. Oculis is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$13.11M	13.35	-$124.02M	-$14.36	N/A
Oculis	$1.45M	469.04	-$119.44M	-$2.13	N/A

In the previous week, Tonix Pharmaceuticals had 1 more articles in the media than Oculis. MarketBeat recorded 2 mentions for Tonix Pharmaceuticals and 1 mentions for Oculis. Tonix Pharmaceuticals' average media sentiment score of 0.17 beat Oculis' score of 0.00 indicating that Tonix Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tonix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oculis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 2.0% of Tonix Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Tonix Pharmaceuticals has a net margin of -839.52% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%
Oculis	-8,460.67%	-56.78%	-45.62%

Tonix Pharmaceuticals has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market. Comparatively, Oculis has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

Summary

Tonix Pharmaceuticals beats Oculis on 10 of the 17 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

In the previous week, Tonix Pharmaceuticals had 2 more articles in the media than Zevra Therapeutics. MarketBeat recorded 2 mentions for Tonix Pharmaceuticals and 0 mentions for Zevra Therapeutics. Tonix Pharmaceuticals' average media sentiment score of 0.17 beat Zevra Therapeutics' score of 0.00 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Zevra Therapeutics	Neutral
Tonix Pharmaceuticals	Neutral

Zevra Therapeutics has a net margin of 101.58% compared to Tonix Pharmaceuticals' net margin of -839.52%. Zevra Therapeutics' return on equity of 51.49% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%

Zevra Therapeutics has higher revenue and earnings than Tonix Pharmaceuticals. Tonix Pharmaceuticals is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	6.68	$83.23M	$1.99	6.05
Tonix Pharmaceuticals	$13.11M	13.35	-$124.02M	-$14.36	N/A

Zevra Therapeutics currently has a consensus price target of $29.29, suggesting a potential upside of 143.44%. Tonix Pharmaceuticals has a consensus price target of $24.00, suggesting a potential upside of 118.58%. Given Zevra Therapeutics' higher possible upside, research analysts clearly believe Zevra Therapeutics is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

Zevra Therapeutics has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market.

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Zevra Therapeutics beats Tonix Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to Aclaris Therapeutics?

Tonix Pharmaceuticals (NASDAQ:TNXP) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 2.0% of Tonix Pharmaceuticals shares are held by insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Aclaris Therapeutics has lower revenue, but higher earnings than Tonix Pharmaceuticals. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$13.11M	13.35	-$124.02M	-$14.36	N/A
Aclaris Therapeutics	$7.83M	99.35	-$64.92M	-$0.56	N/A

Tonix Pharmaceuticals presently has a consensus target price of $24.00, indicating a potential upside of 118.58%. Aclaris Therapeutics has a consensus target price of $11.50, indicating a potential upside of 106.46%. Given Tonix Pharmaceuticals' higher probable upside, equities analysts plainly believe Tonix Pharmaceuticals is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Aclaris Therapeutics has a net margin of -832.58% compared to Tonix Pharmaceuticals' net margin of -839.52%. Aclaris Therapeutics' return on equity of -55.89% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

Tonix Pharmaceuticals has a beta of 1.64, indicating that its share price is 64% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

In the previous week, Aclaris Therapeutics had 1 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 3 mentions for Aclaris Therapeutics and 2 mentions for Tonix Pharmaceuticals. Aclaris Therapeutics' average media sentiment score of 0.76 beat Tonix Pharmaceuticals' score of 0.17 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tonix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aclaris Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aclaris Therapeutics beats Tonix Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

Get Tonix Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNXP vs. The Competition

Export

Metric	Tonix Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$198.14M	$3.07B	$6.89B	$12.28B
Dividend Yield	N/A	2.05%	2.67%	9.39%
P/E Ratio	-0.76	20.20	27.07	23.94
Price / Sales	13.35	340.68	515.45	90.30
Price / Cash	N/A	27.11	26.68	47.25
Price / Book	0.57	4.20	10.42	6.14
Net Income	-$124.02M	$65.94M	$3.60B	$331.74M
7 Day Performance	-0.72%	-3.05%	-1.26%	-1.81%
1 Month Performance	-8.58%	-1.30%	1.07%	-1.44%
1 Year Performance	-75.65%	15.22%	23.61%	16.33%

Tonix Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNXP Tonix Pharmaceuticals	3.819 of 5 stars	$10.98 -11.7%	$24.00 +118.6%	-76.6%	$198.14M	$13.11M	N/A	50
CYRX CryoPort	3.1316 of 5 stars	$15.86 +0.9%	$15.11 -4.7%	+118.5%	$797.58M	$176.18M	11.72	1,186	News Coverage Positive News
CLYM Climb Bio	2.9351 of 5 stars	$13.73 -0.6%	$21.73 +58.2%	+709.3%	$788.47M	N/A	N/A	9
OCS Oculis	2.4741 of 5 stars	$13.48 -1.6%	$38.33 +184.5%	-33.0%	$781.28M	$1.45M	N/A	2
ZVRA Zevra Therapeutics	3.7854 of 5 stars	$13.20 -5.3%	$29.29 +121.9%	-0.3%	$780.50M	$106.47M	6.63	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNXP) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tonix Pharmaceuticals (TNXP) Competitors

TNXP vs. CYRX, CLYM, OCS, ZVRA, and ACRS

How does Tonix Pharmaceuticals compare to CryoPort?

Summary

How does Tonix Pharmaceuticals compare to Climb Bio?

Summary

How does Tonix Pharmaceuticals compare to Oculis?

Summary

How does Tonix Pharmaceuticals compare to Zevra Therapeutics?

Summary

How does Tonix Pharmaceuticals compare to Aclaris Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP vs. The Competition

Tonix Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tonix Pharmaceuticals (TNXP) Competitors

TNXP vs. CYRX, CLYM, OCS, ZVRA, and ACRS

How does Tonix Pharmaceuticals compare to CryoPort?

Is TNXP or CYRX more profitable?

Which has stronger earnings and valuation, TNXP or CYRX?

Which has more risk and volatility, TNXP or CYRX?

Do insiders and institutionals believe in TNXP or CYRX?

Do analysts prefer TNXP or CYRX?

Does the media refer more to TNXP or CYRX?

Summary

How does Tonix Pharmaceuticals compare to Climb Bio?

Do institutionals & insiders hold more shares of TNXP or CLYM?

Which has more risk & volatility, TNXP or CLYM?

Do analysts prefer TNXP or CLYM?

Does the media refer more to TNXP or CLYM?

Which has higher earnings & valuation, TNXP or CLYM?

Is TNXP or CLYM more profitable?

Summary

How does Tonix Pharmaceuticals compare to Oculis?

Do analysts prefer TNXP or OCS?

Which has stronger valuation and earnings, TNXP or OCS?

Does the media refer more to TNXP or OCS?

Do insiders and institutionals believe in TNXP or OCS?

Is TNXP or OCS more profitable?

Which has more volatility and risk, TNXP or OCS?

Summary

How does Tonix Pharmaceuticals compare to Zevra Therapeutics?

Does the media prefer ZVRA or TNXP?

Is ZVRA or TNXP more profitable?

Which has preferable valuation & earnings, ZVRA or TNXP?

Do analysts recommend ZVRA or TNXP?

Which has more volatility and risk, ZVRA or TNXP?

Do institutionals and insiders hold more shares of ZVRA or TNXP?

Summary

How does Tonix Pharmaceuticals compare to Aclaris Therapeutics?

Do institutionals & insiders believe in TNXP or ACRS?

Which has better valuation and earnings, TNXP or ACRS?

Do analysts rate TNXP or ACRS?

Is TNXP or ACRS more profitable?

Which has more risk and volatility, TNXP or ACRS?

Does the media favor TNXP or ACRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP vs. The Competition

Tonix Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools